Physician profile
Wanda B Cade
NPI 1194797415
$3,294.77
in general payments reported to CMS, 2019-2025
28 companies · $552 in 2025
The $552 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $292 · 2021: $474 · 2022: $815 · 2023: $419 · 2024: $417 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $638.01 | 2019-2025 | Bexsero, Shingrix |
| Corium, LLC | $594.35 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $253.10 | 2021-2025 | Qelbree |
| Tris Pharma INC | $239.95 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $206.50 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.41 | 2019-2025 | Elaprase |
| Collegium Pharmaceutical, INC. | $162.18 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $135.06 | 2019-2021 | |
| Kaleo, INC. | $124.28 | 2019-2022 | |
| Pfizer INC. | $113.41 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $112.26 | 2019-2025 | Vaxelis, Gardasil 9, Enflonsia |
| Sobi, INC | $101.44 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $60.83 | 2024-2025 | |
| Adlon Therapeutics L.P. | $60.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.95 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $39.32 | 2022-2023 | Flucelvax Quadrivalent |
| Genentech USA, INC. | $38.35 | 2019-2020 | |
| Abbvie INC. | $26.47 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $26.32 | 2021 | |
| Verrica Pharmaceuticals INC. | $24.27 | 2024 | Ycanth |
| Noven Therapeutics, LLC | $21.02 | 2024 | Xelstrym, Secuado |
| Sun Pharmaceutical Industries INC. | $18.44 | 2020 | |
| Arbor Pharmaceuticals, INC. | $15.51 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.46 | 2022 | |
| Neurelis, INC. | $14.65 | 2023 | Valtoco |
| Cranial Technologies, INC | $14.49 | 2020 | |
| Qiagen, LLC | $13.82 | 2020 | |
| Hologic Sales and Service, LLC | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Cade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.